Journals / Türk Oftalmoloji Dergisi / 2018 / Cilt: 48 - Sayı: 5

Bilateral Serous Macular Detachment After Attempted Suicide with Pregabalin

Pregabalin ile İntihar Girişimi Sonrasında Gelişen Bilateral Seröz Maküla Dekolmanı

Pages
254–257
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To the best of our knowledge, this is the first reported case of bilateral serous macular detachment presumably caused by pregabalin intoxication.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 24-year-old female presented with bilateral vision loss following attempted suicide with pregabalin.
📊
Key Findings & Data:Her best-corrected visual acuity (BCVA) was 20/40 in the right eye and 20/50 in the left eye.
💡
Conclusion & Impact:To the best of our knowledge, this is the first reported case of bilateral serous macular detachment presumably caused by pregabalin intoxication.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 24-year-old female presented with bilateral vision loss following attempted suicide with pregabalin. Her best-corrected visual acuity (BCVA) was 20/40 in the right eye and 20/50 in the left eye. The bilateral visual disturbance was associated with serous macular detachment. Fundus examination of both eyes showed foveal serous retinal detachment, which was confirmed by optical coherence tomography. Topical nepafenac 0.1% eye drops were started as single drop every 8 hours for 4 weeks. One month later, the serous macular detachment had regressed and BCVA increased to 20/20 in both eyes. To the best of our knowledge, this is the first reported case of bilateral serous macular detachment presumably caused by pregabalin intoxication.

Özet

Yirmi dört yaşında kadın hasta pregabalin ile intihar girişimi sonrasında 2 haftadır devam eden bulanık görme şikayeti ile kliniğimizebaşvurdu. Hastanın en iyi düzeltilmiş görme keskinliği (EİDGK) sağ gözde 20/40, sol gözde 20/50 idi. Bilateral görme keskinliğidüşüklüğü seröz maküla dekolmanı ile ilişkiliydi. Optik koherens tomografi ile her 2 gözdeki foveal seröz dekolman tespit edildi.Topikal nepafenak %0,1 göz damlası 8 saatte bir damla olarak başlandı ve 4 hafta süreyle devam edildi. Başvurudan 1 ay sonra, bilateralseröz maküla dekolmanı tamamen geriledi ve EİDGK her 2 gözde 20/20’ye yükseldi. Bildiğimiz kadarıyla bu olgu, literatürde bildirilenpregabalin intoksikasyonuna bağlı gelişen ilk bilateral seröz maküla dekolmanı olgusudur.

🔖

Cite This Article

GÖKTAŞ, E., ŞİMŞEK, Ş., KANDEMİR, B., TANYILDIZ, B., MANGAN, M. S., TANGILNTIZ, A. (2022). Bilateral Serous Macular Detachment After Attempted Suicide with Pregabalin. Türk Oftalmoloji Dergisi, Cilt: 48 - Sayı: 5, 254–257. https://ajindex.com/articles/637792

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, Liu-Dumaw M. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160:533-540.
  2. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexibledose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia. 2005;46:1926-1936.
  3. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137-150.
  4. Di Guilmi MN, Urbano FJ, Inchauspe CG, Uchitel OD. Pregabalin modulation of neurotransmitter release is mediated by change in intrinsic activation/inactivation properties of ca(v)2.1 calcium channels. J Pharmacol Exp Ther. 2011;336:973-982. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491-496.
  5. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017;27:1185-1215. Lyrica® (pregabalin) Prescribing Information. Pfizer Pharmaceuticals LLC. New York, NY 10017. June 2012. http://labeling.pfizer.com/showlabeling. aspx?id=561. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, Messmer S; Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45:20-27.
  6. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137-150.
  7. Vranken JH, Dijkgraaf MG, Kruis MR, van der Vegt MH, Hollmann MW, Heesen M. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008;136:150-157.
  8. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67:771-782.
  9. Aktaş S, Tetikoğlu M, İnan S, Aktaş H, Özcura F. Unilateral hemorrhagic macular infarction associated with marijuana, alcohol and antiepileptic dr